{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:29:45Z","timestamp":1794047385419,"version":"4.8.0"},"reference-count":42,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"5","license":[{"start":{"date-parts":[[2021,7,22]],"date-time":"2021-07-22T00:00:00Z","timestamp":1626912000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Diffuse large B-cell lymphoma (DLBCL) predominantly affects older adults with suboptimal therapeutic outcomes due to increased treatment-related mortality and toxicities in vulnerable patients, clinically defined by geriatric impairments such as functional limitation, multimorbidity, or cognitive deficits. In this prospective pilot study, we evaluated a rituximab\/prednisone prephase treatment strategy in 33 older, vulnerable patients with newly diagnosed DLBCL, defined by either age \u226570 years or age 60-70 years with Karnofsky performance scale (KPS) &lt;80. A single dose of rituximab 375 mg\/m2 between 3-10 days and oral prednisone for at least 5 days prior to the first dose of chemoimmunotherapy was administered. All patients completed prephase treatment and all but one commenced anthracycline-based chemoimmunotherapy. Only one early cycle death occurred. Toxicity events, defined by either unplanned hospitalization, unplanned dose reduction\/delay, or chemotherapy discontinuation, occurred in 22 patients (67%). Sixteen patients (48%) experienced grade 3 or higher non-hematologic toxicities and\/or grade 4 or higher hematologic toxicities. With a median follow-up of 4.4 years, both 5-year progression-free survival and overall survival were at 81% (95% confidence interval: 69-96). Importantly, we found that phenotypic impairments in basic and instrumental activities of daily living, physical function, mobility, KPS, and Cancer and Aging Research Group chemotherapy toxicity risk score were significantly associated with senescence-associated, proinflammatory cytokine milieu which was readily reversed with prephase treatment, potentially explaining its clinical effectiveness. Prephase therapy with rituximab\/prednisone should be considered for all older, vulnerable DLBCL patients prior to curative intent, anthracycline-based chemoimmunotherapy. This trial was registered as clinicaltrials gov. Identifier: NCT 89028394.<\/jats:p>","DOI":"10.3324\/haematol.2021.278719","type":"journal-article","created":{"date-parts":[[2021,7,22]],"date-time":"2021-07-22T05:49:45Z","timestamp":1626932985000},"page":"1144-1152","source":"Crossref","is-referenced-by-count":15,"title":["Prephase rituximab\/prednisone therapy and aging-related, proinflammatory cytokine milieu in older, vulnerable patients with newly diagnosed diffuse large B-cell lymphoma"],"prefix":"10.3324","volume":"107","author":[{"given":"Richard J.","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colette N.","family":"Owens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Drill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Augustine","family":"Iannotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayan","family":"Oliveros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dylan L.","family":"Schick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariela","family":"Noy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John F.","family":"Gerecitano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela R.","family":"Drullinsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip C.","family":"Caron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"Matasar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig","family":"Moskowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Korc-Grodzicki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew D.","family":"Zelenetz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles A.","family":"Salles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul A.","family":"Hamlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2021,7,22]]},"reference":[{"key":"35655","doi-asserted-by":"crossref","unstructured":"Hamlin PA, Satram-Hoang S, Reyes C, Hoang KQ, Guduru SR, Skettino S. Treatment patterns and comparative effectiveness in elderly diffuse large B-cell lymphoma patients: a surveillance, epidemiology, and end results-medicare analysis. Oncologist. 2014; 19(12):1249-1257.","DOI":"10.1634\/theoncologist.2014-0113"},{"key":"35656","doi-asserted-by":"crossref","unstructured":"Levin E, Peng Y, Ji Y, Gilbertson D, Morrison VA. Practice patterns in older patients with diffuse large B-cell lymphoma: a medicare analysis, 2007-2015. J Geriatr Oncol. 2020; 11(8):1344-1348.","DOI":"10.1016\/j.jgo.2020.02.002"},{"key":"35657","doi-asserted-by":"crossref","unstructured":"Mareschal S, Lanic H, Ruminy P, Bastard C, Tilly H, Jardin F. The proportion of activated B-cell like subtype among de novo diffuse large B-cell lymphoma increases with age. Haematologica. 2011; 96(12):1888-1890.","DOI":"10.3324\/haematol.2011.050617"},{"key":"35658","doi-asserted-by":"crossref","unstructured":"Soubeyran PL, Cordoba R. Approaches for vulnerable and frail older patients with diffuse large B-cell lymphomas. Curr Opin Oncol. 2019; 31(5):369-373.","DOI":"10.1097\/CCO.0000000000000559"},{"key":"35659","doi-asserted-by":"crossref","unstructured":"Khan Y, Brem EA. Considerations for the treatment of diffuse large B cell lymphoma in the elderly. Curr Hematol Malig Rep. 2019; 14(4):228-238.","DOI":"10.1007\/s11899-019-00519-7"},{"key":"35660","doi-asserted-by":"crossref","unstructured":"Morrison VA, Hamlin P, Soubeyran P. Approach to therapy of diffuse large B-cell lymphoma in the elderly: the International Society of Geriatric Oncology (SIOG) expert position commentary. Ann Oncol. 2015; 26(6):1058-1068.","DOI":"10.1093\/annonc\/mdv018"},{"key":"35661","doi-asserted-by":"crossref","unstructured":"Pfreundschuh M, Trumper L, Kloess M. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. Blood. 2004; 104(3):626-633.","DOI":"10.1182\/blood-2003-06-2094"},{"key":"35662","doi-asserted-by":"crossref","unstructured":"Pfreundschuh M, Schubert J, Ziepert M. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ Bcell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol. 2008; 9(2):105-116.","DOI":"10.1016\/S1470-2045(08)70002-0"},{"key":"35663","doi-asserted-by":"crossref","unstructured":"Peyrade F, Bologna S, Delwail V. Combination of ofatumumab and reduceddose CHOP for diffuse large B-cell lymphomas in patients aged 80 years or older: an open-label, multicentre, single-arm, phase 2 trial from the LYSA group. Lancet Haematol. 2017; 4(1):e46-e55.","DOI":"10.1016\/S2352-3026(16)30171-5"},{"key":"35664","doi-asserted-by":"crossref","unstructured":"Madsen ML, Due H, Ejskjaer N, Jensen P, Madsen J, Dybkaer K. Aspects of vincristine- induced neuropathy in hematologic malignancies: a systematic review. Cancer Chemother Pharmacol. 2019; 84(3):471-485.","DOI":"10.1007\/s00280-019-03884-5"},{"key":"35665","doi-asserted-by":"crossref","unstructured":"Mohile SG, Dale W, Somerfield MR. Practical assessment and management of vulnerabilities in older patients receiving chemotherapy: ASCO Guideline for Geriatric Oncology. J Clin Oncol. 2018; 36(22):2326-2347.","DOI":"10.1200\/JCO.2018.78.8687"},{"key":"35666","doi-asserted-by":"crossref","unstructured":"DuMontier C, Loh KP, Bain PA. Defining undertreatment and overtreatment in older adults with cancer: a scoping literature review. J Clin Oncol. 2020; 38(22):2558-2569.","DOI":"10.1200\/JCO.19.02809"},{"key":"35667","doi-asserted-by":"crossref","unstructured":"Hurria A, Togawa K, Mohile SG. Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. J Clin Oncol. 2011; 29(25):3457-3465.","DOI":"10.1200\/JCO.2011.34.7625"},{"key":"35668","doi-asserted-by":"crossref","unstructured":"Hurria A, Mohile S, Gajra A. Validation of a prediction tool for chemotherapy toxicity in older adults with cancer. J Clin Oncol. 2016; 34(20):2366-2371.","DOI":"10.1200\/JCO.2015.65.4327"},{"key":"35669","doi-asserted-by":"crossref","unstructured":"Lin RJ, Behera M, Diefenbach CS, Flowers CR. Role of anthracycline and comprehensive geriatric assessment for elderly patients with diffuse large B-cell lymphoma. Blood. 2017; 130(20):2180-2185.","DOI":"10.1182\/blood-2017-05-736975"},{"key":"35670","doi-asserted-by":"crossref","unstructured":"Lopez-Otin C, Blasco MA, Partridge L, Serrano M, Kroemer G. The hallmarks of aging. Cell. 2013; 153(6):1194-1217.","DOI":"10.1016\/j.cell.2013.05.039"},{"key":"35671","doi-asserted-by":"crossref","unstructured":"Gorgoulis V, Adams PD, Alimonti A. Cellular senescence: defining a path forward. Cell. 2019; 179(4):813-827.","DOI":"10.1016\/j.cell.2019.10.005"},{"key":"35672","doi-asserted-by":"crossref","unstructured":"Tchkonia T, Zhu Y, van Deursen J, Campisi J, Kirkland JL. Cellular senescence and the senescent secretory phenotype: therapeutic opportunities. J Clin Invest. 2013; 123(3):966-972.","DOI":"10.1172\/JCI64098"},{"key":"35673","doi-asserted-by":"crossref","unstructured":"Faget DV, Ren Q, Stewart SA. Unmasking senescence: context-dependent effects of SASP in cancer. Nat Rev Cancer. 2019; 19(8):439-453.","DOI":"10.1038\/s41568-019-0156-2"},{"key":"35674","doi-asserted-by":"crossref","unstructured":"Katzman R, Brown T, Fuld P, Peck A, Schechter R, Schimmel H. Validation of a short Orientation-Memory-Concentration Test of cognitive impairment. Am J Psychiatry. 1983; 140(6):734-739.","DOI":"10.1176\/ajp.140.6.734"},{"key":"35675","doi-asserted-by":"crossref","unstructured":"Guigoz Y, Vellas B. The Mini Nutritional Assessment (MNA) for grading the nutritional state of elderly patients: presentation of the MNA, history and validation. Nestle Nutr Workshop Ser Clin Perform Programme. 1999; 1:3-11.","DOI":"10.1159\/000062967"},{"key":"35676","doi-asserted-by":"crossref","unstructured":"Lakshmaiah KC, Asati V, Babu KG. Role of prephase treatment prior to definitive chemotherapy in patients with diffuse large B-cell lymphoma. Eur J Haematol. 2018; 100(6):644-648.","DOI":"10.1111\/ejh.13068"},{"key":"35677","doi-asserted-by":"crossref","unstructured":"Juul MB, Jensen PH, Engberg H. Treatment strategies and outcomes in diffuse large B-cell lymphoma among 1011 patients aged 75 years or older: a Danish population-based cohort study. Eur J Cancer. 2018; 99:86-96.","DOI":"10.1016\/j.ejca.2018.05.006"},{"key":"35678","doi-asserted-by":"crossref","unstructured":"Klepin HD. Ready for prime time: role for geriatric assessment to improve quality of care in hematology practice. Blood. 2019; 134(23):2005-2012.","DOI":"10.1182\/blood.2019001299"},{"key":"35679","doi-asserted-by":"crossref","unstructured":"Abel GA, Klepin HD. Frailty and the management of hematologic malignancies. Blood. 2018; 131(5):515-524.","DOI":"10.1182\/blood-2017-09-746420"},{"key":"35680","doi-asserted-by":"crossref","unstructured":"Liu MA, DuMontier C, Murillo A. Gait speed, grip strength, and clinical outcomes in older patients with hematologic malignancies. Blood. 2019; 134(4):374-382.","DOI":"10.1182\/blood.2019000758"},{"key":"35681","doi-asserted-by":"crossref","unstructured":"Hshieh TT, Jung WF, Grande LJ. Prevalence of cognitive impairment and association with survival among older patients with hematologic cancers. JAMA Oncol. 2018; 4(5):686-693.","DOI":"10.1001\/jamaoncol.2017.5674"},{"key":"35682","doi-asserted-by":"crossref","unstructured":"Saad M, Loh KP, Tooze JA. Geriatric assessment and survival among older adults receiving postremission therapy for acute myeloid leukemia. Blood. 2020; 136(23):2715-2719.","DOI":"10.1182\/blood.2020005498"},{"key":"35683","doi-asserted-by":"crossref","unstructured":"Tucci A, Martelli M, Rigacci L. Comprehensive geriatric assessment is an essential tool to support treatment decisions in elderly patients with diffuse large B-cell lymphoma: a prospective multicenter evaluation in 173 patients by the Lymphoma Italian Foundation (FIL). Leuk Lymphoma. 2015; 56(4):921-926.","DOI":"10.3109\/10428194.2014.953142"},{"key":"35684","doi-asserted-by":"crossref","unstructured":"Merli F, Luminari S, Rossi G. Outcome of frail elderly patients with diffuse large Bcell lymphoma prospectively identified by Comprehensive Geriatric Assessment: results from a study of the Fondazione Italiana Linfomi. Leuk Lymphoma. 2014; 55(1):38-43.","DOI":"10.3109\/10428194.2013.788176"},{"key":"35685","doi-asserted-by":"crossref","unstructured":"Bai JF, Han HX, Feng R. Comprehensive geriatric assessment (CGA): a simple tool for guiding the treatment of older adults with diffuse large B-cell lymphoma in China. Oncologist. 2020; 25(8):e1202-e1208.","DOI":"10.1634\/theoncologist.2019-0738"},{"key":"35686","doi-asserted-by":"crossref","unstructured":"Olivieri A, Gini G, Bocci C. Tailored therapy in an unselected population of 91 elderly patients with DLBCL prospectively evaluated using a simplified CGA. Oncologist. 2012; 17(5):663-672.","DOI":"10.1634\/theoncologist.2011-0355"},{"key":"35687","doi-asserted-by":"crossref","unstructured":"Spina M, Balzarotti M, Uziel L. Modulated chemotherapy according to modified comprehensive geriatric assessment in 100 consecutive elderly patients with diffuse large B-cell lymphoma. Oncologist. 2012; 17(6):838-846.","DOI":"10.1634\/theoncologist.2011-0417"},{"key":"35688","doi-asserted-by":"crossref","unstructured":"Merli F, Luminari S, Tucci A. Simplified geriatric assessment in older patients with diffuse large B-cell lymphoma: the Prospective Elderly Project of the Fondazione Italiana Linfomi. J Clin Oncol. 2021; 39(11):1214-1222.","DOI":"10.1200\/JCO.20.02465"},{"key":"35689","doi-asserted-by":"crossref","unstructured":"Bowcock SJ, Fontana V, Patrick HE. Very poor performance status elderly patients with aggressive B cell lymphomas can benefit from intensive chemotherapy. Br J Haematol. 2012; 157(3):391-393.","DOI":"10.1111\/j.1365-2141.2011.08987.x"},{"key":"35690","doi-asserted-by":"crossref","unstructured":"Voog E, Bienvenu J, Warzocha K. Factors that predict chemotherapy-induced myelosuppression in lymphoma patients: role of the tumor necrosis factor ligandreceptor system. J Clin Oncol. 2000; 18(2):325-331.","DOI":"10.1200\/JCO.2000.18.2.325"},{"key":"35691","doi-asserted-by":"crossref","unstructured":"Dlouhy I, Filella X, Rovira J. High serum levels of soluble interleukin-2 receptor (sIL2-R), interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF) are associated with adverse clinical features and predict poor outcome in diffuse large B-cell lymphoma. Leuk Res. 2017; 59:20-25.","DOI":"10.1016\/j.leukres.2017.05.014"},{"key":"35692","doi-asserted-by":"crossref","unstructured":"Zhong H, Chen J, Cheng S. Prognostic nomogram incorporating inflammatory cytokines for overall survival in patients with aggressive non-Hodgkin's lymphoma. EBioMedicine. 2019; 41:167-174.","DOI":"10.1016\/j.ebiom.2019.02.048"},{"key":"35693","doi-asserted-by":"crossref","unstructured":"Loh KP, Tooze JA, Nicklas BJ. Inflammatory biomarkers, geriatric assessment, and treatment outcomes in acute myeloid leukemia. J Geriatr Oncol. 2020; 11(3):410-416.","DOI":"10.1016\/j.jgo.2019.03.014"},{"key":"35694","doi-asserted-by":"crossref","unstructured":"Justice JN, Nambiar AM, Tchkonia T. Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study. EBioMedicine. 2019; 40:554-563.","DOI":"10.1016\/j.ebiom.2018.12.052"},{"key":"35695","doi-asserted-by":"crossref","unstructured":"Chen Y, Liu S, Leng SX. Chronic low-grade inflammatory phenotype (CLIP) and senescent immune dysregulation. Clin Ther. 2019; 41(3):400-409.","DOI":"10.1016\/j.clinthera.2019.02.001"},{"key":"35696","doi-asserted-by":"crossref","unstructured":"Kurzrock R, Voorhees PM, Casper C. A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease. Clin Cancer Res. 2013; 19(13):3659-3670.","DOI":"10.1158\/1078-0432.CCR-12-3349"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2021.278719\/73526","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2021.278719\/74410","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/10338\/73526","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:00:01Z","timestamp":1794045601000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2021.278719"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,22]]},"references-count":42,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,5,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2021.278719","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7,22]]}}}